Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer

被引:0
作者
Shen, Qiang [1 ]
Murakami, Kiichi [1 ]
Sotov, Valentin [1 ]
Butler, Marcus [1 ,2 ,3 ]
Ohashi, Pamela S. [1 ,4 ,5 ]
Reedijk, Michael [1 ,5 ,6 ]
机构
[1] Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
[4] Univ Toronto, Dept Immunol, Med Sci Bldg,1 Kings Coll Circle,Room 7205, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, MaRS Ctr, Dept Med Biophys, Toronto Med Discovery Tower,101 Coll St,Room 15-70, Toronto, ON M5G 2M9, Canada
[6] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 8-411, Toronto, ON M5G 2M9, Canada
基金
加拿大健康研究院;
关键词
TUMOR-ASSOCIATED MACROPHAGES; SIGNALING PATHWAY; CELLS; INFLAMMATION; NIVOLUMAB; THERAPY; INVASIVENESS; EXPRESSION; MICROENVIRONMENT; PEMBROLIZUMAB;
D O I
10.1126/sciadv.ado8275
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant Notch, which is a defining feature of triple-negative breast cancer (TNBC) cells, regulates intercellular communication in the tumor immune microenvironment (TIME). This includes tumor-associated macrophage (TAM) recruitment through Notch-dependent cytokine secretion, contributing to an immunosuppressive TIME. Despite the low response rate of TNBC to immune checkpoint blockade (ICB), here, we report that inhibition of Notch-driven cytokine-mediated programs reduces TAMs and induces responsiveness to sequentially delivered ICB. This is characterized by the emergence of GrB+ cytotoxic T lymphocytes (CTLs) in the primary tumor. A more impressive effect of sequential treatment is observed in the lung where TAM depletion and increased CTLs are accompanied by near-complete abolition of metastases. This is due to (i) therapeutic reduction in Notch-dependent, prometastatic circulating factors released by the primary tumor, and (ii) elevated PD ligand 1 (PD-L1) in lung metastases, rendering them profoundly sensitive to ICB. These findings highlight the potential of combination cytokine inhibition and ICB as an immunotherapeutic strategy in TNBC.
引用
收藏
页数:14
相关论文
共 50 条
[31]   Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer [J].
Lee, Kyung-min ;
Lin, Chang-Ching ;
Servetto, Alberto ;
Bae, Joonbeom ;
Kandagatla, Vishal ;
Ye, Dan ;
Kim, GunMin ;
Sudhan, Dhivya R. ;
Mendiratta, Saurabh ;
Ericsson, Paula I. Gonzalez ;
Balko, Justin M. ;
Lee, Jeon ;
Barnes, Spencer ;
Malladi, Venkat S. ;
Tabrizi, Siamak ;
Reddy, Sangeetha M. ;
Yum, Seoyun ;
Chang, Ching-Wei ;
Hutchinson, Katherine E. ;
Yost, Susan E. ;
Yuan, Yuan ;
Chen, Zhijian J. ;
Fu, Yang-Xin ;
Hanker, Ariella B. ;
Arteaga, Carlos L. .
CANCER IMMUNOLOGY RESEARCH, 2022, 10 (07) :829-843
[32]   Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy [J].
Wang, Zhiren ;
Cordova, Leyla Estrella ;
Chalasani, Pavani ;
Lu, Jianqin .
MOLECULAR PHARMACEUTICS, 2022, 19 (12) :4665-4674
[33]   Promotion of triple negative breast cancer immunotherapy by combining bioactive radicals with immune checkpoint blockade [J].
Chen, Meixu ;
Song, Linlin ;
Zhou, Yao ;
Xu, Tianyue ;
Sun, Ting ;
Liu, Zhihui ;
Xu, Zihan ;
Zhao, Yujie ;
Du, Peixin ;
Ma, Yingying ;
Huang, Liwen ;
Chen, Xiaoting ;
Yang, Guang ;
Jing, Jing ;
Shi, Hubing .
ACTA BIOMATERIALIA, 2025, 194 :305-322
[34]   New Targets for Triple-Negative Breast Cancer [J].
Herold, Christina I. ;
Anders, Carey K. .
ONCOLOGY-NEW YORK, 2013, 27 (09) :846-854
[35]   TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer [J].
Bhola, Neil E. ;
Balko, Justin M. ;
Dugger, Teresa C. ;
Kuba, Maria Gabriela ;
Sanchez, Violeta ;
Sanders, Melinda ;
Stanford, Jamie ;
Cook, Rebecca S. ;
Arteaga, Carlos L. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (03) :1348-1358
[36]   Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment [J].
Wu, Jiayi ;
Wang, Wei ;
Gao, Lu ;
Shao, Xiying ;
Wang, Xiaojia .
CANCER, 2024, 130 :1449-1463
[37]   Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade [J].
Qin, Ye ;
Vasilatos, Shauna N. ;
Chen, Lin ;
Wu, Hao ;
Cao, Zhishen ;
Fu, Yumei ;
Huang, Min ;
Vlad, Anda M. ;
Lu, Binfeng ;
Oesterreich, Steffi ;
Davidson, Nancy E. ;
Huang, Yi .
ONCOGENE, 2019, 38 (03) :390-405
[38]   Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects [J].
Thomas, Remy ;
Al-Khadairi, Ghaneya ;
Decock, Julie .
FRONTIERS IN ONCOLOGY, 2021, 10
[39]   NOTCH4 Is a Potential Therapeutic Target for Triple-negative Breast Cancer [J].
Nagamatsu, Iori ;
Onishi, Hideya ;
Matsushita, Shojiro ;
Kubo, Makoto ;
Kai, Masaya ;
Imaizumi, Akira ;
Nakano, Kenji ;
Hattori, Masami ;
Oda, Yoshinao ;
Tanaka, Masao ;
Katano, Mitsuo .
ANTICANCER RESEARCH, 2014, 34 (1A) :69-80
[40]   Inhibition of UCH-L1 enhances immunotherapy efficacy in triple-negative breast cancer by stabilizing PD-L1 [J].
He, Linhao ;
He, Jiaying ;
Jiang, Ting ;
Gong, Rong ;
Wan, Xiaoya ;
Duan, Mingwu ;
Chen, Zonglin ;
Cheng, Yan .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2025, 1000